Silence Therapeutics
 | This article contains content that is written like an advertisement. (January 2022) |
Pharmaceuticals | |
| Founded | 1994 |
|---|---|
| Headquarters | Hammersmith, London |
Number of employees | 120 |
| Website | www.silence-therapeutics.com |
Silence Therapeutics (
Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.[2]
Profile
Silence Therapeutics develops medicines related to
hematological diseases, and zerlasiran (formerly SLN360), designed to address the unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a), a key genetic risk factor for cardiovascular disease. The company reported in November 2023 that a phase 1 study showed injection of repeated doses reduced patients' baseline of Lp(a) by up to 99 per cent for 90 days after. [4]
Partnerships
Silence Therapeutics is under the stewardship of CEO Craig Tooman, and has established partnerships with pharmaceutical companies, such as
Hansoh Pharma, among others.[5]
References
- ^ "Google Finance Stock Exchange listing for Silence Therapeutics".
- ^ "About us". silence-therapeutics.com. Archived from the original on 26 March 2023. Retrieved 26 June 2023.
- doi:10.1038/418244a. Retrieved 26 June 2023.
- ^ Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
- ^ "Transcript : Silence Therapeutics plc Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023|
